

international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I controlled substances to the above listed company.

Dated: February 22, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-04026 Filed 3-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals, Inc.**

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 5, 2019. Such persons may also file a written request for a

hearing on the application on or before April 5, 2019.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 24, 2018, Patheon Pharmaceuticals, Inc., 2110 E Galbraith Road, Cincinnati, Ohio 45237, has re-applied to be registered as a bulk manufacturer of the Schedule I controlled substance Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance.

The Gamma Hydroxybutyric Acid will be produced during the process of converting gamma-butyrolactone (GBL)

into a new product for development. The company plans to manufacture the above listed controlled substance as Active Pharmaceutical Ingredient (API) that will be further synthesized into dosage forms of a new product. No other activities for this drug code are authorized for this registration.

Dated: February 18, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-04029 Filed 3-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice.

Company	FR Docket	Published
Cambrex Charles City .....	83 FR 49579 .....	October 2, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing their physical security systems, verifying their compliance with state and local laws, and reviewing their background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a

registration as a bulk manufacturer to the above listed company.

Dated: February 22, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019-04027 Filed 3-5-19; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-392]

**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of schedule I or schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as bulk manufacturers of schedule I or schedule II controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

Company	FR docket	Published
Patheon API Manufacturing, Inc. ....	83 FR 58596	November 20, 2018.
Insys Manufacturing, LLC .....	83 FR 60899	November 27, 2018.
Cayman Chemical Company .....	83 FR 60900	November 27, 2018.
Noramco Inc. ....	83 FR 60898	November 27, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of the listed registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR

1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Dated: February 18, 2019.  
**John J. Martin,**  
*Assistant Administrator.*  
 [FR Doc. 2019-04033 Filed 3-5-19; 8:45 am]  
**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**  
**Drug Enforcement Administration**  
**[Docket No. DEA-392]**  
**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of schedule I controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

Company	FR Docket	Published
Insys Manufacturing, LLC .....	83 FR 54611 .....	October 30, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of the listed registrant to manufacture the applicable basic classes of schedule I and II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR

1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: February 18, 2019.  
**John J. Martin,**  
*Assistant Administrator.*  
 [FR Doc. 2019-04032 Filed 3-5-19; 8:45 am]  
**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**  
**Drug Enforcement Administration**  
**[Docket No. DEA-392]**  
**Bulk Manufacturer of Controlled Substances Registration**

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as bulk manufacturer of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previously published notice is listed in the table below. No comments or objections were submitted for this notice.

Company	FR Docket	Published
Organix, Inc .....	83 FR 58601 .....	November 20, 2018.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent

with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance

of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and